This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Conflicted on These Healthcare Names: United Therapeutics (UTHR), DENTSPLY SIRONA (XRAY) and Climb Bio (CLYM)

Tipranks - Tipranks - Sat Jun 13, 7:56AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on United Therapeutics (UTHR), DENTSPLY SIRONA (XRAY) and Climb Bio (CLYM).

Introducing TipRanks MCP for Agents

United Therapeutics (UTHR)

Leerink Partners analyst Roanna Ruiz reiterated a Buy rating on United Therapeutics today and set a price target of $700.00. The company’s shares closed last Thursday at $545.40.

According to TipRanks.com, Ruiz is a 2-star analyst with an average return of 0.0% and a 47.0% success rate. Ruiz covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics, Vir Biotechnology, and Cormedix. ;'>

United Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $673.40, a 23.6% upside from current levels. In a report issued on May 29, H.C. Wainwright also maintained a Buy rating on the stock with a $660.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

DENTSPLY SIRONA (XRAY)

In a report released today, Michael Cherny from Leerink Partners maintained a Hold rating on DENTSPLY SIRONA. The company’s shares closed last Thursday at $10.14.

According to TipRanks.com, Cherny is a 4-star analyst with an average return of 4.7% and a 54.9% success rate. Cherny covers the Healthcare sector, focusing on stocks such as Hims & Hers Health, CVS Health, and Align Tech. ;'>

Currently, the analyst consensus on DENTSPLY SIRONA is a Hold with an average price target of $13.65, a 37.0% upside from current levels. In a report issued on June 4, TipRanks – Anthropic also upgraded the stock to Hold with a $9.50 price target.

Climb Bio (CLYM)

In a report released today, Laura Chico from Wedbush maintained a Buy rating on Climb Bio, with a price target of $17.00. The company’s shares closed last Thursday at $10.91, close to its 52-week high of $11.55.

According to TipRanks.com, Chico is a 5-star analyst with an average return of 11.2% and a 51.0% success rate. Chico covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Sionna Therapeutics, Inc., and Ultragenyx Pharmaceutical. ;'>

Climb Bio has an analyst consensus of Strong Buy, with a price target consensus of $22.00, implying a 105.2% upside from current levels. In a report issued on June 8, Guggenheim also initiated coverage with a Buy rating on the stock with a $35.00 price target.

Read More on UTHR:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).